Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion

Nature Genetics

Volumn 45, Issue 7, 2013, Pages 739-746

  Wang, Guocan ^a,b,c   Lunardi, Andrea ^a   Zhang, Jiangwen ^d   Chen, Zhenbang ^c,g   Ala, Ugo ^a   Webster, Kaitlyn A ^a   Tay, Yvonne ^a   Gonzalez Billalabeitia, Enrique ^a   Egia, Ainara ^a   Shaffer, David R ^c,h   Carver, Brett ^c   Liu, Xue Song ^a   Taulli, Riccardo ^a   Kuo, Winston Patrick ^e   Nardella, Caterina ^a,c   Signoretti, Sabina ^a,f   Cordon Cardo, Carlos ^c,i   Gerald, William L ^c   Pandolfi, Pier Paolo ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d HARVARD UNIVERSITY   (United States)

^e HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g MEHARRY MEDICAL COLLEGE   (United States)

^h ALBANY MEDICAL CENTER   (United States)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR SOX9;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL INVASION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTO ONCOGENE; SENESCENCE; TUMOR CELL; TUMOR GENE; TUMOR INVASION; ZBTB7A GENE;

ANIMALS; CELL AGING; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; SOX9 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS;

EID: 84879645484     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.2654     Document Type: Article

References (75)

1. Maeda, T. et al. Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature 433, 278-285 (2005).
2. Pendergrast, P.S., Wang, C., Hernandez, N. & Huang, S. FBI-1 can stimulate HIV-1 Tat activity and is targeted to a novel subnuclear domain that includes the Tat-P-TEFb-containing nuclear speckles. Mol. Biol. Cell 13, 915-929 (2002).
3. Kukita, A. et al. Osteoclast-derived zinc finger (OCZF) protein with POZ domain, a possible transcriptional repressor, is involved in osteoclastogenesis. Blood 94, 1987-1997 (1999).
4. Davies, J.M. et al. Novel BTB/POZ domain zinc-finger protein, LRF, is a potential target of the LAZ-3/BCL-6 oncogene. Oncogene 18, 365-375 (1999).
5. Chen, X., Whitney, E.M., Gao, S.Y. & Yang, V.W. Transcriptional profiling of Kruppel-like factor 4 reveals a function in cell cycle regulation and epithelial differentiation. J. Mol. Biol. 326, 665-677 (2003).
6. Costoya, J.A. et al. Essential role of Plzf in maintenance of spermatogonial stem cells. Nat. Genet. 36, 653-659 (2004).
7. He, X. et al. The zinc finger transcription factor Th-POK regulates CD4 versus CD8 T-cell lineage commitment. Nature 433, 826-833 (2005).
8. Pasqualucci, L. et al. Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood 101, 2914-2923 (2003).
9. Sun, G. et al. The zinc finger protein cKrox directs CD4 lineage differentiation during intrathymic T cell positive selection. Nat. Immunol. 6, 373-381 (2005).
10. Jiang, L. et al. Overexpression of proto-oncogene FBI-1 activates membrane type 1-matrix metalloproteinase in association with adverse outcome in ovarian cancers. Mol. Cancer 9, 318 (2010).
11. Aggarwal, A. et al. Expression of leukemia/lymphoma-related factor (LRF/POKEMON) in human breast carcinoma and other cancers. Exp. Mol. Pathol. 89, 140-148 (2010).
12. Qu, H. et al. ZBTB7 overexpression contributes to malignancy in breast cancer. Cancer Invest. 28, 672-678 (2010).
13. Vredeveld, L.C., Rowland, B.D., Douma, S., Bernards, R. & Peeper, D.S. Functional identification of LRF as an oncogene that bypasses RASV12-induced senescence via upregulation of CYCLIN E. Carcinogenesis 31, 201-207 (2010).
14. Zhao, Z.H. et al. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results. Lung Cancer 62, 113-119 (2008).
15. Chen, Z. et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725-730 (2005).
16. Wu, X. et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech. Dev. 101, 61-69 (2001).
17. Trotman, L.C. et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 1, E59 (2003).
18. Alimonti, A. et al. Subtle variations in Pten dose determine cancer susceptibility. Nat. Genet. 42, 454-458 (2010).
19. Ding, Z. et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470, 269-273 (2011).
20. Majumder, P.K. et al. A prostatic intraepithelial neoplasia-dependent p27Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 14, 146-155 (2008).
21. Chen, Z. et al. Differential p53-independent outcomes of p19Arf loss in oncogenesis. Sci. Signal. 2, ra44 (2009).
22. Zhang, Z., Rosen, D.G., Yao, J.L., Huang, J. & Liu, J. Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression. Mod. Pathol. 19, 1339-1343 (2006).
23. Xie, W.F., Zhang, X., Sakano, S., Lefebvre, V. & Sandell, L.J. Trans-activation of the mouse cartilage-derived retinoic acid-sensitive protein gene by Sox9. J. Bone Miner. Res. 14, 757-763 (1999).
24. Wang, D.H. et al. Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia. Gastroenterology 138, 1810-1822 (2010).
25. Dudek, K.A., Lafont, J.E., Martinez-Sanchez, A. & Murphy, C.L. Type II collagen expression is regulated by tissue-specific miR-675 in human articular chondrocytes. J. Biol. Chem. 285, 24381-24387 (2010).
26. Ho Sui, S.J., Fulton, D.L., Arenillas, D.J., Kwon, A.T. & Wasserman, W.W. oPOSSUM: integrated tools for analysis of regulatory motif over-representation. Nucleic Acids Res. 35, W245-W252 (2007).
27. Ho Sui, S.J. et al. oPOSSUM: identification of over-represented transcription factor binding sites in co-expressed genes. Nucleic Acids Res. 33, 3154-3164 (2005).
28. Kwon, A.T., Arenillas, D.J., Worsley Hunt, R. & Wasserman, W.W. oPOSSUM-3: advanced analysis of regulatory motif over-representation across genes or ChIP-Seq datasets. G3 (Bethesda) 2, 987-1002 (2012).
29. Mootha, V.K. et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267-273 (2003).
30. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).
31. Thomsen, M.K. et al. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res. 70, 979-987 (2010).
32. Wang, H. et al. SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res. 68, 1625-1630 (2008).
33. Murakami, S., Kan, M., McKeehan, W.L. & de Crombrugghe, B. Up-regulation of the chondrogenic Sox9 gene by fibroblast growth factors is mediated by the mitogen-activated protein kinase pathway. Proc. Natl. Acad. Sci. USA 97, 1113-1118 (2000).
34. Müller, H. et al. Deleted in malignant brain tumors 1 is present in the vascular extracellular matrix and promotes angiogenesis. Arterioscler. Thromb. Vasc. Biol. 32, 442-448 (2012).
35. Robbe, C. et al. DMBT1 expression and glycosylation during the adenoma-carcinoma sequence in colorectal cancer. Biochem. Soc. Trans. 33, 730-732 (2005).
36. Kang, W. et al. Induction of DMBT1 expression by reduced ERK activity during a gastric mucosa differentiation-like process and its association with human gastric cancer. Carcinogenesis 26, 1129-1137 (2005).
37. Cheung, W. et al. Application of a global proteomic approach to archival precursor lesions: deleted in malignant brain tumors 1 and tissue transglutaminase 2 are upregulated in pancreatic cancer precursors. Pancreatology 8, 608-616 (2008).
38. Tynan, S. et al. The putative tumor suppressor deleted in malignant brain tumors 1 is an estrogen-regulated gene in rodent and primate endometrial epithelium. Endocrinology 146, 1066-1073 (2005).
39. Kang, W. & Reid, K.B. DMBT1, a regulator of mucosal homeostasis through the linking of mucosal defense and regeneration? FEBS Lett. 540, 21-25 (2003).
40. Schmidt, J. & Bosserhoff, A.K. Processing of MIA protein during melanoma cell migration. Int. J. Cancer 125, 1587-1594 (2009).
41. Bosserhoff, A.K., Echtenacher, B., Hein, R. & Buettner, R. Functional role of melanoma inhibitory activity in regulating invasion and metastasis of malignant melanoma cells in vivo. Melanoma Res. 11, 417-421 (2001).
42. Bosserhoff, A.K. et al. Active detachment involves inhibition of cell-matrix contacts of malignant melanoma cells by secretion of melanoma inhibitory activity. Lab. Invest. 83, 1583-1594 (2003).
43. Guba, M. et al. Overexpression of melanoma inhibitory activity (MIA) enhances extravasation and metastasis of A-mel 3 melanoma cells in vivo. Br. J. Cancer 83, 1216-1222 (2000).
44. Stahlecker, J. et al. MIA as a reliable tumor marker in the serum of patients with malignant melanoma. Anticancer Res. 20, 5041-5044 (2000).
45. Cai, X. & Cullen, B.R. The imprinted H19 noncoding RNA is a primary microRNA precursor. RNA 13, 313-316 (2007).
46. Tsang, W.P. et al. Oncofetal H19-derived miR-675 regulates tumor suppressor RB in human colorectal cancer. Carcinogenesis 31, 350-358 (2010).
47. Chicas, A. et al. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell 17, 376-387 (2010).
48. Sun, H. et al. E2f binding-deficient Rb1 protein suppresses prostate tumor progression in vivo. Proc. Natl. Acad. Sci. USA 108, 704-709 (2011).
49. Lunardi, A. et al. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation therapy resistance in prostate cancer. Nat. Genet. published online; doi:10.1038/ng.2650 (2 June 2013).
50. Luo, J.H. et al. Gene expression analysis of prostate cancers. Mol. Carcinog. 33, 25-35 (2002).
51. Liu, P. et al. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res. 66, 4011-4019 (2006).
52. LaTulippe, E. et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 62, 4499-4506 (2002).
53. Taylor, B.S. et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18, 11-22 (2010).
54. Grasso, C.S. et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487, 239-243 (2012).
55. Stephenson, A.J. et al. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer 104, 290-298 (2005).
56. Lapointe, J. et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc. Natl. Acad. Sci. USA 101, 811-816 (2004).
57. Vanaja, D.K., Cheville, J.C., Iturria, S.J. & Young, C.Y. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res. 63, 3877-3882 (2003).
58. Arredouani, M.S. et al. Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. Clin. Cancer Res. 15, 5794-5802 (2009).
59. Tomlins, S.A. et al. Integrative molecular concept modeling of prostate cancer progression. Nat. Genet. 39, 41-51 (2007).
60. Wallace, T.A. et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res. 68, 927-936 (2008).
61. Poliseno, L. et al. The proto-oncogene LRF is under post-transcriptional control of MiR-20a: implications for senescence. PLoS ONE 3, e2542 (2008).
62. Poliseno, L. et al. Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci. Signal. 3, ra29 (2010).
63. Ren, B. et al. MCM7 amplification and overexpression are associated with prostate cancer progression. Oncogene 25, 1090-1098 (2006).
64. Sterner, J.M., Dew-Knight, S., Musahl, C., Kornbluth, S. & Horowitz, J.M. Negative regulation of DNA replication by the retinoblastoma protein is mediated by its association with MCM7. Mol. Cell Biol. 18, 2748-2757 (1998).
65. Tomlins, S.A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648 (2005).
66. Clark, J.P. & Cooper, C.S. ETS gene fusions in prostate cancer. Nat. Rev. Urol. 6, 429-439 (2009).
67. Tomlins, S.A. et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur. Urol. 56, 275-286 (2009).
68. Navone, N.M. et al. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J. Urol. 161, 304-308 (1999).
69. Qian, J. et al. Loss of p53 and c-myc overrepresentation in stage T2-3N1-3M0 prostate cancer are potential markers for cancer progression. Mod. Pathol. 15, 35-44 (2002).
70. Carver, B.S. et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet. 41, 619-624 (2009).
71. King, J.C. et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat. Genet. 41, 524-526 (2009).
72. De Santa Barbara, P. et al. Direct interaction of SRY-related protein SOX9 and steroidogenic factor 1 regulates transcription of the human anti-Mullerian hormone gene. Mol. Cell Biol. 18, 6653-6665 (1998).
73. Root, D.E., Hacohen, N., Hahn, W.C., Lander, E.S. & Sabatini, D.M. Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat. Methods 3, 715-719 (2006).
74. Maeda, T. et al. LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis. Dev. Cell 17, 527-540 (2009).
75. Drabkin, H.A. et al. Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia 16, 186-195 (2002).